Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Aug;66(2):402–404. doi: 10.1038/bjc.1992.277

A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer.

A R Dixon 1, L Jackson 1, S Chan 1, J Haybittle 1, R W Blamey 1
PMCID: PMC1977824  PMID: 1503915

Abstract

Sixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to receive four course of mitozantrone, 14 mg m-2 (n = 30) intravenously every 3 weeks (9 weeks total) or megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disease control for a minimum period of 6 months i.e., lack of progression; seven patients (23%) showed objective response to mitozantrone compared to four (13%) receiving megesterol. Non-progressive disease occurred in all sites, including visceral metastases and receptor negative patients. There were no significant differences between treatment groups in the median time (5 months each) to disease progression response duration or survival (13 months megesterol, 11 months mitozantrone) from commencing second-line therapy. Toxicity was considerably higher in the mitozantrone group. Second-line hormonal therapies can produce similar therapeutic results as those achieved from a short course of a 'short option' single agent cytotoxic in patients who were previously thought hormone insensitive. Provided that the patient does not have life threatening disease a trial of megesterol acetate is worth consideration in that it does not prejudice subsequent response to combination cytotoxic chemotherapy.

Full text

PDF
402

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackledge G. R., Latief T., Mould J. J., Spooner D., Morrison M. Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment. Eur J Cancer Clin Oncol. 1986 Sep;22(9):1091–1094. doi: 10.1016/0277-5379(86)90012-x. [DOI] [PubMed] [Google Scholar]
  2. Harris A. L., Cantwell B. M., Carmichael J., Wilson R., Farndon J., Dawes P., Ghani S., Evans R. G. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 1990 Jan 27;335(8683):186–190. doi: 10.1016/0140-6736(90)90277-c. [DOI] [PubMed] [Google Scholar]
  3. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  4. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  5. Leyden M., Cheng Z. M., Collins J., Russell I., Andrews J., Sullivan J. Mitoxantrone treatment in advanced breast cancer. Aust N Z J Surg. 1984 Feb;54(1):21–24. doi: 10.1111/j.1445-2197.1984.tb06679.x. [DOI] [PubMed] [Google Scholar]
  6. Mouridsen H. T., Cornbleet M., Stuart-Harris R., Smith I., Coleman R., Rubens R., McDonald M., Rainer H., van Oosterom A., Smyth J. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. Invest New Drugs. 1985;3(2):139–148. doi: 10.1007/BF00174161. [DOI] [PubMed] [Google Scholar]
  7. Powles T. J., Coombes R. C., Smith I. E., Jones J. M., Ford H. T., Gazet J. C. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet. 1980 Mar 15;1(8168 Pt 1):580–582. doi: 10.1016/s0140-6736(80)91066-1. [DOI] [PubMed] [Google Scholar]
  8. Robertson J. F., Williams M. R., Todd J. H., Blamey R. W. Mitoxantrone--a useful palliative therapy in advanced breast cancer. Am J Clin Oncol. 1989 Oct;12(5):393–396. doi: 10.1097/00000421-198910000-00006. [DOI] [PubMed] [Google Scholar]
  9. Robertson J. F., Williams M. R., Todd J., Nicholson R. I., Morgan D. A., Blamey R. W. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol. 1989 Mar;25(3):469–475. doi: 10.1016/0277-5379(89)90259-9. [DOI] [PubMed] [Google Scholar]
  10. Ross M. B., Buzdar A. U., Blumenschein G. R. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 1;49(3):413–417. doi: 10.1002/1097-0142(19820201)49:3<413::aid-cncr2820490303>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  11. Walker K. J., Bouzubar N., Robertson J., Ellis I. O., Elston C. W., Blamey R. W., Wilson D. W., Griffiths K., Nicholson R. I. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res. 1988 Nov 15;48(22):6517–6522. [PubMed] [Google Scholar]
  12. Williams M. R., Todd J. H., Nicholson R. I., Elston C. W., Blamey R. W., Griffiths K. Survival patterns in hormone treated advanced breast cancer. Br J Surg. 1986 Sep;73(9):752–755. doi: 10.1002/bjs.1800730925. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES